Article and Video CATEGORIES

Cancer Journey

Search By

Lung Cancer Video Library - Blood-Based Mutation Testing: Circulating Tumor Cells and Tumor DNA
Wed, 01/20/2016 - 06:00
GRACE Videos and Articles
Dr. Ed Kim from the Levine Cancer Institute reviews the potential advantages and current limitations of blood-based testing for molecular markers using circulating tumor cells and circulating tumor DNA in identifying clinically important mutations.



We know there are challenges in trying to obtain biopsies, especially when you’ve already been diagnosed and had treatment, and then the tumor stops responding to the therapy that’s given. We like to do repeat biopsies because we know that the tumor can change over time, after being exposed to different types of therapies. That can sometimes be challenging, and add some risk to patients because it is an invasive procedure — many times we use a needle that will go through the chest, into the tumor, to try and extract enough tissue to make these measurements. Emerging technology that has really been very popular the last few years has been trying to utilize your blood to measure these markers. You’ll hear terminologies like circulating tumor cells, or CTCs, circulating DNA — a lot of different things that are measuring, trying to identify things in your blood that may be representative of your tumor in your chest, or your liver, or where it may be.

One of the technologies is called circulating tumor cells — in this, you are actually trying to isolate these cancer cells in the blood. Some of the technologies are cell search systems, in which you isolate, what we call, through a filter, these tumor cells — that is a bit challenging, it has been inconsistent with some of the results. Also, circulating cell-free DNA is another technology — this, again, is trying to measure small pieces of DNA that are shed from the tumor, and it’s a little easier to pick up that, as opposed to actual, whole cancer cells, in the bloodstream.

There are some commercial tests out there — Guardant360 is one of them, that’s based, again, on the technologies discussed in the NGS section, that would be next-gen sequencing, and also OncoBEAM or Sysmex Inostics — these are also commercial tests, and I can tell you there are many more that are coming. Right now, I would not view them, necessarily, as your first choice, over getting a tumor biopsy. However, a lot of the quality analytics that have been done have shown that they can measure almost as accurately in the bloodstream, using these technologies, as one would taking tumor tissue through a procedure, using an interventional procedure like a bronchoscopy or interventional radiology.


Video Language

Next Previous link

Previous PostNext Post

Related Content

Forum Discussions

Hi JW and welcome to Grace. I'm sorry you're going through this but hopefully and probably this isn't cancer. There is so much going on anatomically in that area that the...

Hi and welcome to Grace. I'm so sorry about your mom's situation, it's very complicated and not at all reasonable for us to comment on all that is being taken into...

Hi Scruboak, I will ask Dr. West to comment, it may be tomorrow. He's an expert in the field and will have thoughtful input. The fact that it was caught and...

I asked Dr. West and he said that this is a question he can't answer, we don't have studies that give details that specific. He said to his knowledge, that this...

Thank you so much, Janine. It helps me to just chill overall.

It's surprising how a little piece of intel can make everything else in life easier.

Hi Scrappy,


Below I've pasted my comment from facebook. Google is a double-edged sword, you can find anything but without some context, it can be tough to digest. We get...

Recent Comments

Hi JW and welcome to Grace. …
By JanineT Forum … on Mon, 05/16/2022 - 10:52
All's good
By JanineT Forum … on Sat, 05/14/2022 - 15:10
Can Pancoast affect both sides of the body?
By JanineT Forum … on Wed, 05/11/2022 - 19:49
Hi and welcome to Grace. I…
By JanineT Forum … on Sun, 04/24/2022 - 08:41